Approval · Notice of Compliance 23914 · 2020
HADLIMA: Notice of Compliance 23914
Issued July 15, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 23914
- Date
- July 15, 2020
- Company
- Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional manufacturing facilities
- Canadian reference product
- HUMIRA (ADALIMUMAB) (AbbVie Corporation)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HADLIMA | Not yet assigned | — |
| HADLIMA PUSHTOUCH | Not yet assigned | — |
Medicinal ingredients
- ADALIMUMAB 40 MG per 0.8ML